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A B S T R A C T
Hepatocellular carcinoma (HCC) mostly occurs in chronic liver disease and cirrhosis. Liver resection and liver trans-
plantation (LT) represent potentially curative treatments of choice and if not feasible, palliative strategies such as percu-
taneous interventional techniques (PITs) and chemotherapy (ChT) are considered. Elevated alfa-fetoprotein, typical im-
aging pattern, needle core biopsy (NCB) and fine needle aspiration cytology (FNAC) complement diagnostic assessment
of HCC. We have retrospectively analyzed all patients with contraindications for NCB in which HCC was diagnosed by
FNAC during consecutive 5 years in our hospital. Ultrasound guided FNAC provided a safe method of approach and, ex-
cept for mild transitory discomfort at the site of puncture, no complications were documented. The diagnosis was estab-
lished on May-Grünwald-Giemsa (MGG) stained aspirates and additional immunocytochemistry. Of our 62 patients,
HCC developed in 61.3% cirrhotic and 38.7% non-cirrhotic livers. In the setting of cirrhosis 18.4% of patients underwent
LT, 15.8% PITs, 26.3% ChT and 39.5% symptomatic therapy. In non-cirrhotic setting 46% of patients underwent liver re-
section, and PIT, ChT, and symptomatic therapy were applied in 4%, 25%, 25% of cases, respectively. Pathohistology of
resected and explanted livers (18 cases) confirmed the initial diagnosis made on FNAC. Since only early stage of HCC
has a better prognosis, every effort should be made to establish prompt and accurate diagnosis. Our observations demon-
strate that FNAC offers minimally invasive, rapid and uncomplicated diagnostic approach, with sensitivity from 67% to
93% and specificity from 96% to 100%. FNAC, is of utmost importance in the setting of abnormal coagulation tests and
ascites commonly seen in advanced liver disease, facilitating diagnostic workup and treatment decisions.
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Introduction
Hepatocellular carcinoma (HCC) is the fourth most
common cancer in the world and its incidence is still ris-
ing. It accounts for about 90% of all primary liver cancers
and mostly occurs in the setting of chronic liver disease
and cirrhosis. Several important risk factors for HCC
have been identified: male gender (3.7:1 men to wo-
men)1, higher age (mean age at presentation between 50
and 60 years)2, chronic liver disease (chronic hepatitis or
cirrhosis) of any cause3–5, hepatitis B virus (HBV) infec-
tion – (chronic HBV infection is the predominant global
environmental cause of chronic hepatitis or cirrhosis,
whereas 25% of infected or more will develop HCC)6,7,
hepatitis C virus (HCV) infection (80% of acutely in-
fected become chronic carriers, and about 60% develop
chronic hepatitis of which 20% progress to cirrhosis over
a period of 20–25 years, and a proportion of these develop
HCC)8,9, iron overload: hereditary hemochromatosis
(HH) and dietary iron overload (with a relative risk of
greater than 200)10, aflatoxin (mycotoxin produced by
the fungi Aspergillus flavis), nonalcoholic fatty liver dis-
ease (NASH) and diabetes mellitus (DM)11, inherited
metabolic disorders: alpha-1 antitrypsin (a1AT) deficien-
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cy, hereditary tyrosinemia type 1 (HT1), glycogen storage
diseases and Wilson’s disease12–15.
Although elevated level of serum alpha-fetoprotein
and a typical imaging pattern (demonstrated by ultra-
sound, computer tomography – CT, magnetic resonance –
MR and angiography) may be sufficient for diagnosis, in
inconclusive cases tissue diagnosis is mandatory. Needle
core biopsy (NCB) and fine needle aspiration cytology
(FNAC) both can provide definitive morphological as-
sessment. HCC is typically diagnosed late in its course,
and the median survival following diagnosis is approxi-
mately 6 to 20 months16. Treatment strategies, depend-
ing on tumor extent and underlying liver dysfunction, in-
clude liver resection or transplantation, percutaneous
interventional techniques (PITs), chemotherapy (ChT)
and symptomatic therapy.
Materials and Methods
This study was carried out by the multidisciplinary
team of tertiary Gastroenterology centre from »Merkur«
University Hospital. We retrospectively identified all
HCC patients diagnosed only by FNAC at our institution
in the period from January 2004 to July 2009. Data col-
lected from patients’ medical records specified clinical,
laboratory, imaging and cytological results. Diagnostic
assessment included imaging studies (ultrasound, CT or
MR imaging) and serum alpha-fetoprotein level. Ultra-
sound guided FNAC with the CHIBA needle of 0.7 mm
(22 gauge) was performed in patients with clinical sug-
gestion of HCC with contraindications for NCB; abnor-
mal coagulation parameters, refractory ascites or lack of
a safe access. The cytological smears were stained by the
standard May-Grünwald-Giemsa method (MGG) (Figure
1a and b). Immunocytochemical staining was performed
by LSAB method with monoclonal antibodies (DAKO),
applying a panel of a-fetoprotein (Figure 1c), BerEP4,
CD31, CK8, CK18 (Figure1d), and in selected cases, CK
5/6, CK7, CK 19, CK 20, CD117, desmin, SMA, chro-
mogranin, synaptophysin, thyroid transcription factor-1
(TTF-1), Ca19,9, CEA etc. for the diagnosis of HCC and
distinction of HCC from metastatic tumors (MC) or to
identify the primary tumor site of MC. Statistical analy-
ses were performed using MedCalc for Windows, version
9.5.0.0 (MedCalc Software, Mariakerke, Belgium). Data
were analyzed with Mann Whitney test, c2-test and Fi-
sher’s exact test. Differences were considered significant
when two sided p<0.05.
Results
In period from 2004 to 2009, all patients with contra-
indications for NCB in which HCC was diagnosed by
FNAC are analyzed. FNAC was performed under the
guidance of ultrasound. No serious post-procedural com-
plications were documented, except for mild transitory
discomfort at the site of puncture. Summarized data of
all our patients are presented in Table 1. 62 patients
were included, mean age of 63 years (range 47–86, SD
13). The majority of patients (61.3%) developed HCC in
cirrhotic liver, whereas 38.7% in non-cirrhotic form of
parenchymal liver disease. Dominant gender in both
groups was men: 81.6% in cirrhotic group (CG) and
83.3% in non-cirrhotic group (NCG). HCC developed in
significantly earlier age in CG (mean age 62±9.1) than in
NCG (mean age 70±9.3, Mann Whitney, p<0.02). In the
majority of patients in CG (63.2%) the etiology of under-
lying liver disease was known; alcohol in 47.4% and viral
diseases (HBV and HCV) in 15.8% of cases. In compari-
son, in 83.3% of cases in NCG, the etiology of the liver
disease remained unknown and in only 8.3% it was alco-
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Figure 1. Fine needle aspiration cytology of hepatocellular carcinoma: a) well-differentiated (MGG, 1000x), b) poorly differentiated
(MGG, x1000), c) a-feto protein positive cells (immunocytochemistry, LSAB, 1000x), d) Cytokeratin 18 positive cells (immunocytoche-
mistry, LSAB, x1000).
hol and 8.3% viral infection. There was no statistically
significant difference between the groups regarding tu-
mor presentation (multifocal or solitary) at the time of
diagnosis (c2, p=0.56).
In the setting of decompensated cirrhosis, 18.4% of
patients which met Milan criteria, underwent liver trans-
plantation, 15.8% underwent PIT, 26.3% were treated
with chemotherapy and 39.5% with symptomatic ther-
apy. In non-cirrhotic group HCC was treated in 45.8% of
cases by liver resection, in 25% with chemotherapy, in
25% with symptomatic therapy and in 4% by PIT. Patho-
histological analysis of resected (11 cases) and explanted
livers (seven cases) confirmed the initial diagnosis made
on FNA specimens.
Discussion
There is a general consensus that periodic abdominal
ultrasound (every six months) and the measurement of
serum AFP level in surveillance of high risk groups can
detect HCC in its early stage, which is associated with
better prognosis17. However, significant proportion of
HCC lesions are not associated with elevated AFP and al-
though imaging methods show a typical imaging pattern,
that finding is not always patognomonic, especially for
small and hypovascular tumors18–20. Therefore, additio-
nal morphological assessment should be made either by
FNAC or NCB. Although NCB is considered a gold stan-
dard for identification of HCC, in the clinical practice, es-
pecially in the setting of advanced parenchymal liver dis-
ease, it is not always a feasible method. Major obstacles
for its use are: low platelet count, abnormal coagulation
parameters, refractory ascites or localisation of lesion
with no safe access route. Limited by aforementioned pa-
rameters, diagnostic workup may be delayed or inter-
rupted enabling further progression of malignant disease
and restraining treatment options. FNAC results in a lit-
tle liver damage and has a high safety. The occurrence
rate of complications ranges from 0.05% to 0.16% and in-
cludes bleeding, bile leakage, infection and death21. In the-
ory, pulling out the needle after aspiration procedure
may result in further seeding of the tumor cells. None of
these complications were observed in our survey. The
specificity and positive predictive value of FNAC is ran-
ges from 96% to 100% and its sensitivity ranges from 67
to 93%22–24. These results are comparable to the accuracy
of NCB (sensitivity range 61 to 94%)25,26.
Liver resection is the treatment of choice for HCC in
non-cirrhotic and Child A cirrhotic patients, but in the
setting of decompensated liver disease, liver transplanta-
tion (LT) represents an effective treatment as it simulta-
neously treats the tumor and the underlying liver dis-
ease. If not feasible, percutaneous interventional tech-
niques (PITs); percutaneous ethanol injection (PEI),
radiofrequency ablation (RFA), selected transcatheter
arterial chemoembolization (TACE) provide optional
choices of treatment. Liver resection or LT are consid-
ered best treatment options for HCC because of potential
complete recovery. However these procedures are mainly
limited by the size of tumor and the possibility of disease
dissemination. Therefore every effort should be made to
enable the accurate diagnosis in the early stage of the
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TABLE 1
DATA FOR PATIENTS WITH HEPATOCELULLAR CARCINOMA
Characteristics Cirrhotic group % (n) Non-cirrhotic group % (n) p-value
Patients 61.3% (38) 38.7% (24)
Female 18.4% (7) 16.7% (4) 0.89
Male 81.6% (31) 83.3% (20)
Age, mean±SD, 62±9.1 70±9.3 <0.002*
Etiology
Alcohol 47.4% (18) 8.3% (2) 0.004*
Viruses (HBV+HCV) 15.8% (6) 8.3% (2) 0.64
Undetermined 36.8% (14) 83.3% (20) <0.001*
Tumor presentation
Mutifocal 52.6% (20) 41.7% (10) 0.56
Solitary 47.4% (18) 58.3% (14)
Therapy
Hepatic resection 0 45.8% (11)
OLT 18.4% (7) 0
PITs 15.8% (6) 4.2% (1) 0.32
Chemotherapy 26.3% (10 ) 25% (6) 0.86
Symptomatic therapy 39.5% (15 ) 25% (6) 0.34
*statistically significant, OLT – orthotopic liver transplantation, PIT – percutaneous interventional techniques
disease. Postponing or interrupting the diagnostic pro-
cess due to contraindication for certain methods restricts
treatment to palliative modalities such as chemotherapy
and symptomatic therapy. HCC is a chemotherapy-re-
fractory tumor and cytotoxic effect is modest in patients
with HCC. No single regimen has emerged as superior to
any other (doxorubicin, mitoxantrone, cisplatin-based
and gemcitabine-based combination regimens) and in
general, the duration of benefit is limited. Although mo-
lecular pathogenesis of HCC remains still poorly under-
stood, molecularly targeted therapy (sorafenib) has emer-
ged in recent years for treatment of advanced stage of the
disease.
Out of 62 HCC patients with contraindications for
NCB, detection of HCC by FNAC in 64.2% (18.4% CG
and 45.8% NGC) of patients still in early stage of the ma-
lignant disease allowed application of potentially curati-
ve treatment options (LT and resection). Our observations
demonstrate that in spite of obstacles in advanced liver
disease, FNAC offers safe and effective diagnostic appro-
ach steering the treatment to more beneficial prognosis.
Therefore since only early stage of the disease offers
potentially curative treatment options it is imperative,
especially in high risk group patients, to perform inten-
sive screening for HCC and, if suspected, every effort
should be made to establish early and accurate diagnosis.
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ULOGA CITOLO[KE PUNKCIJE U STRATEGIJI HEPATOCELULARNOG KARCINOMA
– ISKUSTVO JEDNOG CENTRA
S A @ E T A K
Hepatocelularni karcinom (HCC) se razvija uglavnom u kroni~noj bolesti jetre ili cirozi. Resekcija i transplantacija
jetre (LT) su potencijalne metode izlje~enja HCC, no ukoliko nisu primjenjive, dolaze u obzir palijativne strategije poput
perkutane interventne tehnike (PITs) i kemoterapije (ChT). Povi{eni alfa-fetoprotein; tipi~ni morfolo{ki prikaz, iglena
biopsija (core needle biopsy – NCB) i citolo{ka punkcija (fine needle aspiration cytology – FNAC) komplementarne su
metode u dijagnostici HCC. Analizirali smo sve bolesnike s kontaindikacijom za NCB kod kojih je HCC dijagnosticiran
citolo{kom punkcijom u razdoblju od 2004.–2009. godine u na{oj ustanovi. Citolo{ka punkcija u~injena je pod kontro-
lom ultrazvuka te osim prolazne nelagode na mjestu punkcije nisu opa`ene druge komplikacije. Dijagnoza je postavlje-
na na citolo{kim razmazima obojenim May-Grunwald-Giemsa bojenjem i imunocitokemijski. Od ukupno 62 bolesnika,
HCC se razvio u 61,3% bolesnika s cirozom jetre te u 38,7% bolesnika bez ciroze jetre. Kod ciroze jetre u 18,4% bo-
lesnika izvr{ena je LT, 15,8% PITs, 26,3% ChT te je u 39,5% provedena simptomatska terapija. U skupini bolesnika bez
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ciroze, kod 46% bolesnika je izvr{ena resekcija, u 4% primjenjen je PITs, u 25% ChT i u 25% simptomatska terapija.
Patohistolo{ka analiza reseciranih i eksplantirannih jetri (18 slu~ajeva) potvrdila je citolo{ku dijagnozu. Budu}i rani
stadiji bolesti imaju bolju prognozu, potrebna je brza i to~na dijagnostika. Na{a zapa`anja ukazuju da je FNAC mini-
malno invazivna, brza i jednostavna dijanosti~ka metoda sa osjetljivo{}u od 67% do 93% i specifi~no{}u od 96% do 100.
Citolo{ka punkcija, naro~ito u slu~ajevima uzapredovale bolesti jetre s komplikacijama (lo{a koagulacija i ascites) omo-
gu}uje rano postavljanje dijagnoze, te time i raniji po~etak lije~enja.
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